<code id='FC150BE988'></code><style id='FC150BE988'></style>
    • <acronym id='FC150BE988'></acronym>
      <center id='FC150BE988'><center id='FC150BE988'><tfoot id='FC150BE988'></tfoot></center><abbr id='FC150BE988'><dir id='FC150BE988'><tfoot id='FC150BE988'></tfoot><noframes id='FC150BE988'>

    • <optgroup id='FC150BE988'><strike id='FC150BE988'><sup id='FC150BE988'></sup></strike><code id='FC150BE988'></code></optgroup>
        1. <b id='FC150BE988'><label id='FC150BE988'><select id='FC150BE988'><dt id='FC150BE988'><span id='FC150BE988'></span></dt></select></label></b><u id='FC150BE988'></u>
          <i id='FC150BE988'><strike id='FC150BE988'><tt id='FC150BE988'><pre id='FC150BE988'></pre></tt></strike></i>

          Home / Wikipedia / focus

          focus


          focus

          author:comprehensive    Page View:665
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In